Cargando…

Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH

In non-alcoholic steatohepatitis (NASH), decreased nitric oxide and increased endothelin-1 (ET-1, also known as EDN1) released by sinusoidal endothelial cells (LSEC) induce hepatic stellate cell (HSC) contraction and contribute to portal hypertension (PH). Statins improve LSEC function, and ambrisen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bravo, Miren, Raurell, Imma, Barberá, Aurora, Hide, Diana, Gil, Mar, Estrella, Federico, Salcedo, María Teresa, Augustin, Salvador, Genescà, Joan, Martell, María
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Company of Biologists Ltd 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8188885/ https://www.ncbi.nlm.nih.gov/pubmed/34014280 http://dx.doi.org/10.1242/dmm.048884

Ejemplares similares

Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH
por: Bravo, Miren, et al.
Publicado: (2019)

Proteomic Analysis of Dysfunctional Liver Sinusoidal Endothelial Cells Reveals Substantial Differences in Most Common Experimental Models of Chronic Liver Diseases
por: Gil, Mar, et al.
Publicado: (2023)

A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo
por: Pinheiro, Iris, et al.
Publicado: (2022)

Inhibition of Neuronal Apoptosis and Axonal Regression Ameliorates Sympathetic Atrophy and Hemodynamic Alterations in Portal Hypertensive Rats
por: Ezkurdia, Nahia, et al.
Publicado: (2014)

A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats
por: Rodríguez, Sarai, et al.
Publicado: (2017)

Liver steatosis induces portal hypertension regardless of fibrosis in patients with NAFLD: A proof of concept case report
por: Rivera-Esteban, Jesús, et al.
Publicado: (2022)

Ambrisentan for the treatment of pulmonary arterial hypertension
por: Casserly, Brian, et al.
Publicado: (2009)

Ambrisentan-induced severe asymptomatic thrombocytopenia
por: Kigitovica, Dana, et al.
Publicado: (2020)

A review of pulmonary arterial hypertension: role of ambrisentan
por: Barst, Robyn J
Publicado: (2007)

Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes
por: Elshaboury, Soha M, et al.
Publicado: (2013)

Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia
por: Schroeder, Thies, et al.
Publicado: (2017)

Hemodynamic changes in hepatic sinusoids of hepatic steatosis mice
por: Fan, Jing, et al.
Publicado: (2019)

The Crosstalk Between Liver Sinusoidal Endothelial Cells and Hepatic Microenvironment in NASH Related Liver Fibrosis
por: Du, Wei, et al.
Publicado: (2022)

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension
por: Safdar, Zeenat
Publicado: (2011)

Open label study of ambrisentan in patients with exercise pulmonary hypertension
por: Segrera, Sergio A., et al.
Publicado: (2017)

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
por: Escribano-Subias, Pilar, et al.
Publicado: (2019)

Prognostic Evaluation of Patients with Acute Variceal Bleeding
por: Augustin, Salvador, et al.
Publicado: (2011)

Hyperlipidemia May Synergize with Hypomethylation in Establishing Trained Immunity and Promoting Inflammation in NASH and NAFLD
por: Drummer, Charles I. V., et al.
Publicado: (2021)

Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model
por: Klaebel, Julie Hviid, et al.
Publicado: (2019)

Evaluation of herb-drug interaction of ambrisentan with shikonin based on UPLC-MS/MS
por: Lan, Tian, et al.
Publicado: (2021)

Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin
por: Cestari, Roberta Natália, et al.
Publicado: (2020)

Stability-Indicating RP-HPLC Method for the Determination of Ambrisentan and Tadalafil in Pharmaceutical Dosage Form
por: Patel, Jayvadan K., et al.
Publicado: (2014)

Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
por: Hakamata, A, et al.
Publicado: (2016)

Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy
por: Abston, Eric, et al.
Publicado: (2020)

Angiodiversity and organotypic functions of sinusoidal endothelial cells
por: Koch, Philipp-Sebastian, et al.
Publicado: (2021)

Ambrisentan, an endothelin receptor type A-selective antagonist, inhibits cancer cell migration, invasion, and metastasis
por: Kappes, Lucy, et al.
Publicado: (2020)

Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model
por: Rabiee, Anahita, et al.
Publicado: (2022)

Hepatic safety of ambrisentan alone and in combination with tadalafil: a post-hoc analysis of the AMBITION trial
por: Patel, Krishna R., et al.
Publicado: (2018)

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Gong, Su-Gang, et al.
Publicado: (2018)

Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Chen, Jingyuan, et al.
Publicado: (2021)

Effects of aging on liver microcirculatory function and sinusoidal phenotype
por: Maeso‐Díaz, Raquel, et al.
Publicado: (2018)

The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression
por: Juárez‐Fernández, María, et al.
Publicado: (2023)

Immunonano-Lipocarrier-Mediated Liver Sinusoidal Endothelial Cell-Specific RUNX1 Inhibition Impedes Immune Cell Infiltration and Hepatic Inflammation in Murine Model of NASH
por: Tripathi, Dinesh Mani, et al.
Publicado: (2021)

Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
por: Udoh, Utibe-Abasi S., et al.
Publicado: (2022)

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
por: Coghlan, John Gerry, et al.
Publicado: (2017)

Corrigendum: The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-Word Prospective Study
por: Chen, Yusi, et al.
Publicado: (2022)

Nash vek /
por: Nappelʹbaum, Moisei Solomonovich, 1869-1958
Publicado: (1984)

Nash manifolds
por: Shiota, Masahiro
Publicado: (1987)

Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better
por: Hirsova, Petra
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rm9n502h91l4d0p0so9hsb6151